GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Nastech Pharmaceutical's Intranasal Insulin Formulation Enters into Clinical Trial

  • Nastech Pharmaceutical initiated a Phase I pharmacokinetic study designed to evaluate the safety, bioavailability, and glucose response of Nastech’s rapid-acting intranasal insulin formulation. The study will compare Nastech’s intranasal formulation to an approved injectable product and to a recently approved new dosage form, Exubera® (insulin human [rDNA origin]) Inhalation Powder.

    Nastech believes its insulin nasal spray could provide patients with a convenient, needle-free alternative while avoiding possible pulmonary side effects or long-term toxicity associated with the inhalation of insulin.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

The Uproar over Fetal Tissue Donations

Does your academic or industry lab use fetal tissue in its research?

More »